Q-omics provides the consensus-scored OLFML3 profile across patient tissues and cancer cell-line models. OLFML3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, OLFML3 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, OLFML3 protein abundance shows 35,321 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight UCEC, and KIRP as cancer lineages where OLFML3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OLFML3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OLFML3 survival associations across molecular data types. OLFML3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OLFML3 RNA expression–survival associations across cancer types. High OLFML3 expression shows unfavorable associations in LGG, BLCA and STAD, but favorable associations in UCEC, UCS and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for OLFML3 RNA expression.
This table summarizes OLFML3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRP for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for OLFML3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OLFML3 shows lower tumor expression in KIRP, BLCA, UCEC, LUSC, LIHC and KICH. The KIRP box plot shows higher OLFML3 RNA expression in normal versus tumor tissue (log2 FC = −1.921, t-test p < 0.001).
This table shows molecular features associated with OLFML3 in patient tissues and cancer cell lines. In patient samples, OLFML3 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, OLFML3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SKIN.
